NasdaqCM:VKTX

Stock Analysis Report

Executive Summary

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Viking Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.4%

NasdaqCM:VKTX

0.6%

US Biotechs

1.3%

US Market


1 Year Return

-31.2%

NasdaqCM:VKTX

-10.3%

US Biotechs

2.0%

US Market

VKTX underperformed the Biotechs industry which returned -10.8% over the past year.

VKTX underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

VKTXIndustryMarket
7 Day-1.4%0.6%1.3%
30 Day4.7%-1.2%3.9%
90 Day-14.4%-0.1%3.4%
1 Year-31.2%-31.2%-9.5%-10.3%4.2%2.0%
3 Year458.6%458.6%7.1%3.5%47.2%37.6%
5 Yearn/a3.3%-1.7%60.5%42.9%

Price Volatility Vs. Market

How volatile is Viking Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Viking Therapeutics undervalued based on future cash flows and its price relative to the stock market?

1.79x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Viking Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Viking Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Viking Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Viking Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Viking Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Viking Therapeutics is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Viking Therapeutics expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

-29.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Viking Therapeutics is high growth as no revenue estimate data is available.

Viking Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Viking Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Viking Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Viking Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Viking Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Viking Therapeutics performed over the past 5 years?

-0.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Viking Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Viking Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Viking Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Viking Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Viking Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Viking Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Viking Therapeutics's financial position?


Financial Position Analysis

Viking Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Viking Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Viking Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Viking Therapeutics had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.6449100179591E+18x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Viking Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.

Viking Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 18.2% each year.


Next Steps

Dividend

What is Viking Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Viking Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Viking Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Viking Therapeutics has not reported any payouts.

Unable to verify if Viking Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Viking Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Viking Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Brian Lian (53yo)

7yrs

Tenure

US$1,403,283

Compensation

Dr. Brian Lian, Ph.D., has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian serves as Director of Seelos Therapeutics, Inc. He served as Managi ...


CEO Compensation Analysis

Brian's remuneration is about average for companies of similar size in United States of America.

Brian's compensation has increased whilst company is loss making.


Management Age and Tenure

1.7yrs

Average Tenure

53yo

Average Age

The average tenure for the Viking Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

5.3yrs

Average Tenure

59.5yo

Average Age

The tenure for the Viking Therapeutics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$5,034,25028 Sep 18
Ligand Pharmaceuticals Incorporated
EntityCompany
Shares262,881
Max PriceUS$19.15

Ownership Breakdown


Management Team

  • Greg Zante (48yo)

    Senior Vice President of Finance

    • Tenure: 0.08yrs
  • Brian Lian (53yo)

    President

    • Tenure: 7yrs
    • Compensation: US$1.40m
  • Michael Morneau (54yo)

    Vice President of Finance & Administration

    • Tenure: 1.4yrs
    • Compensation: US$619.56k
  • Amy Broidrick

    Senior Vice President of Corporate Development

    • Tenure: 2.7yrs
  • Marianne Mancini

    Senior Vice President of Clinical Operations

    • Tenure: 1.7yrs

Board Members

  • Scott Hecker

    Scientific Advisor

    • Tenure: 0yrs
  • Matt Foehr (46yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: US$81.82k
  • J. Singleton (67yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: US$105.22k
  • Stephen Webster (58yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: US$106.79k
  • Charlie Rowland (61yo)

    Director

    • Tenure: 2.2yrs
    • Compensation: US$104.04k
  • Alan Cherrington

    Scientific Advisor

    • Tenure: 0yrs
  • Zan Fleming

    Scientific Advisor

    • Tenure: 0yrs
  • Brian Lian (53yo)

    President

    • Tenure: 7yrs
    • Compensation: US$1.40m
  • David Bullough

    Scientific Advisor

    • Tenure: 0yrs
  • Lawson MacArtney (62yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$121.91k

Company Information

Viking Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Viking Therapeutics, Inc.
  • Ticker: VKTX
  • Exchange: NasdaqCM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$516.306m
  • Shares outstanding: 72.21m
  • Website: https://www.vikingtherapeutics.com

Number of Employees


Location

  • Viking Therapeutics, Inc.
  • 12340 El Camino Real
  • Suite 250
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VKTXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2015
1VTDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2015
0VQALSE (London Stock Exchange)YesCommon StockGBUSDApr 2015

Biography

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally avai ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:17
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.